Unknown Manufacturer
GlyphAllo (SPT-300, also known as Glyph Allopregnanolone) is a novel Glyphed oral prodrug of the endogenous neurosteroid allopregnanolone, developed by Seaport Therapeutics for the potential treatment of major depressive disorder (MDD), with or without anxious distress.
GlyphAllo (SPT-300, also known as Glyph Allopregnanolone) is a novel Glyphed oral prodrug of the endogenous neurosteroid allopregnanolone, developed by Seaport Therapeutics for the potential treatment of major depressive disorder (MDD), with or without anxious distress.
1 associated conditions
